Determinants of ventricular arrhythmias in human explanted hearts with dilated cardiomyopathy

Background The molecular and cellular determinants of ventricular tachycardia (VT) in patients with nonischaemic dilated cardiomyopathy (NIDCM) remain poorly defined. Materials and methods We examined 20 NIDCM hearts where VT was reported in 10 cases and VT was absent in 10 cases, using a double‐bli...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of clinical investigation Vol. 45; no. 12; pp. 1286 - 1296
Main Authors Parajuli, Nirmal, Valtuille, Lucas, Basu, Ratnadeep, Famulski, Konrad S., Halloran, Philip F., Sergi, Consolato, Oudit, Gavin Y.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.12.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background The molecular and cellular determinants of ventricular tachycardia (VT) in patients with nonischaemic dilated cardiomyopathy (NIDCM) remain poorly defined. Materials and methods We examined 20 NIDCM hearts where VT was reported in 10 cases and VT was absent in 10 cases, using a double‐blinded case–control study design, and assessed the molecular and cellular features of the adverse myocardial remodelling. Results Explanted hearts from patients with VT showed greater hypertrophic changes based on cardiomyocyte cross‐sectional area and expression of disease markers, and increased myocardial fibrosis which extended into the left ventricular and right ventricular outflow tract regions. The VT group also showed increased oxidative stress with reduction in reduced glutathione levels. Connexin 43 levels in the intercalated discs showed increased levels in the VT group with reduced phosphorylation. Microarray mRNA analysis of gene expression in the left ventricle (LV) free wall revealed several families of genes which were differentially upregulated or downregulated in hearts with documented VT compared to hearts without VT. Notably, we identified reduced expression of the Ca2+‐activated K+ channel (KCNN2) and increased expression of the transient receptor potential cation channel 7 (TRPM7) and intracellular chloride channel 3. Western blot analysis on LV membrane fractions showed reduced KCNN2 and increased TRPM7 levels in hearts with VT. Conclusions In explanted human hearts with NIDCM, VT is associated with greater hypertrophy, oxidative stress and myocardial fibrosis, differential gene expression, and altered ion channel levels indicative of a distinctive adverse myocardial remodelling process associated with clinically significant VT.
Bibliography:Canadian Institutes of Health Research (CIHR)
Figure S1. Additional representative images of the regional assessment of myocardial fibrosis using Movat's pentachrome staining showing increased bluish-greenish (a) and yellowish (b) stained areas in the right ventricular outflow tract (RVOT), left ventricular outflow tract (LVOT) and the interventricular septum (IVS). Quantification of the pentachrome images (c). *P < 0.05 compared with the non-VT group. Figure S2. Evaluation of the purity of the left ventricular membrane fraction using Western blot analysis for Na+/K+-ATPase, a marker for membrane fraction, and caspase-3, a marker for cytosolic fraction, with the memcode staining representing the loading control. Figure S3. Relative expression of CLIC3 in m-RNA level by microarray (a) and in protein level by Western blots (b). n = 8 in the non-VT and VT groups. R.E., relative expression; R.R., relative ratio; A.U., arbitrary units. The memcode staining represents the loading control and Na+/K+-ATPase, a marker for membrane fraction. Figure S4. Specificity of the connexin-43 and N-cadherin staining in the left ventricular myocardial tissue. Negative control staining seen after incubation using only the secondary antibody (a) while the positive staining using primary antibodies against Cx-43 and N-Cadherin is illustrated in (b). Nuclear staining using DAPI (blue fluorescence) is shown in the middle panel and merged images are shown in the right panels. Scale bar, 50 μm.
ark:/67375/WNG-NJT9DN4N-T
Heart and Stroke Foundation (HSF)
Alberta Innovates - Health Solutions (AIHS)
ArticleID:ECI12549
istex:014B5E79E01923FF2BAE6943758D5A9BFCDA8AA1
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0014-2972
1365-2362
DOI:10.1111/eci.12549